Filing Details
- Accession Number:
- 0001127602-14-024832
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-05 20:43:11
- Reporting Period:
- 2014-08-01
- Filing Date:
- 2014-08-05
- Accepted Time:
- 2014-08-05 19:43:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1145197 | Insulet Corp | PODD | Surgical & Medical Instruments & Apparatus (3841) | 043523891 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1395777 | Duane Desisto | C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-08-01 | 10,000 | $15.16 | 267,184 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2014-08-01 | 10,000 | $15.09 | 277,184 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-08-01 | 20,000 | $34.23 | 257,184 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2014-08-01 | 10,000 | $0.00 | 10,000 | $15.16 |
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2014-08-01 | 10,000 | $0.00 | 10,000 | $15.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,000 | 2020-03-01 | No | 4 | M | Direct | |
| 0 | 2018-03-12 | No | 4 | M | Direct |
Footnotes
- Includes 35,000 restricted stock units granted on April 1, 2012, which vest one-half of the total units on April 1, 2015 and one-half of the total units on April 1, 2016; 45,000 restricted stock units granted on March 1, 2013, which vest one-third of the total units on March 1, 2015, one-third of the total units on March 1, 2016 and one-third of the total units on March 1, 2017; 40,000 performance share units granted on March 1, 2013, which vest one-half of the total units on March 1, 2015 and one-half of the total units on March 1, 2016; and 44,000 restricted stock units granted on March 3, 2014, which vest one-third of the total units on March 3, 2015, one-third of the total units on March 3, 2016 and one-third of the total units on March 3, 2017. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
- Includes an aggregate of 9,494 shares acquired under the Insulet Corporation Amended and Restated 2007 Employee Stock Purchase Plan on the following dates: 219 shares acquired on December 31, 2007; 694 shares acquired on June 30, 2008; 1,429 shares acquired on December 31, 2008; 1,431 shares acquired on June 30, 2009; 772 shares acquired on December 31, 2009; 749 shares acquired on June 30, 2010; 732 shares acquired on December 31, 2010; 532 shares acquired on June 30, 2011; 640 shares acquired on December 30, 2011; 580 shares acquired on June 29, 2012; 589 shares acquired on December 31, 2012; 410 shares acquired on June 28, 2013; 360 shares acquired on December 31, 2013; and 357 shares acquired on June 30, 2014.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2014.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $34.13147 to $35.22417. The reporting Person hereby undertakes, upon request of the Staff of the U.S Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
- This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
Billionaire Hedge Funds
